NEW YORK (GenomeWeb) – In a filing with the US Securities and Exchange Commission this week, Thermo Fisher Scientific reported it recorded $90 million in restructuring and other costs related to its acquisition of Affymetrix. That expense included $11 million for the sale of inventories revalued at the date of acquisition and to conform the accounting policies of Affymetrix with Thermo Fisher's own accounting policies, and $29 million for third-party transaction costs.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.